Furthermore, the NF-κB inhibitor BAY 11-7082 was shown to attenuate NF-κB activation and cell proliferation induced by gefitinib/osimertinib resistance (Figure 5E and 5F), suggesting that gefitinib/osimertinib-resistant cells promote tumor progression through activation of NF-κB pathway. Here, NFKB1 is linked to neoplasm.